Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235395 | 1.00 | CYP1A2 (0.50) | CYP1A2CYP2D6HIF1ALMNAKDM4E | |
| SCHEMBL8256890 | 1.00 | CYP1A2 (0.50) | CYP1A2CYP2D6HIF1ALMNAKDM4E | |
| SCHEMBL14384675 | 1.00 | CYP1A2 (0.50) | CYP1A2CYP2D6HIF1ALMNAKDM4E | |
| SCHEMBL10187512 | 0.85 | TDP1 (0.45) | CYP1A2CYP2D6HIF1ATDP1 | |
| SCHEMBL5495958 | 0.81 | TDP1 (0.45) | CYP2D6TDP1CHRM2CHRM4CHRM5 | |
| SCHEMBL17158431 | 0.81 | AOC3 (0.43) | LMNAAOC3 | |
| SCHEMBL9721750 | 0.81 | KDM4E (0.46) | KDM4EAOC3 | |
| SCHEMBL2744914 | 0.79 | CYP1A2 (0.33) | CYP1A2CYP2D6HIF1A | |
| SCHEMBL7694718 | 0.79 | CYP1A2 (0.33) | CYP1A2CYP2D6HIF1A | |
| SCHEMBL799713 | 0.79 | CYP1A2 (0.33) | CYP1A2CYP2D6HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172905-B1 | Treatment of protein degradation disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-01-08 | — | — | US | disclosed |
| US-9572854-B2 | Treatment of protein degradation disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2016120890-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE SYNTHESIS OF (2S,4R)-4-HYDROXYPIPECOLIC ACID | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-08-04 | — | — | WO | disclosed |
| US-8999289-B2 | Treatment of protein degradation disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2491926-A1 | Treatment of protein degradation disorders | President and Fellows of Harvard College (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2006102557-A2 | TREATMENT OF PROTEIN DEGRADATION DISORDERS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172905-B1 | Treatment of protein degradation disorders | HDAC6, HDAC5, AADAC | CYP1A2 4554/4885CYP2D6 4350/4885HIF1A 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.